NEW YORK, May 8-Robert Williamson has been hired as president and chief operating officer of Eos Biotechnology, the company said yesterday.
He will be responsible for business development at Eos, which is developing therapeutic antibody treatments for oncology, angiogenesis and inflammation.
Eos, based in South San Francisco, Calif., is privately owned.
Williamson comes to Eos from DoubleTwist, where he was promoted from president to CEO in January 2002 in a last-ditch effort to save the struggling company.
Despite salvage efforts, DoubleTwist closed for good in March.
MorphoSys said yesterday that it had added two senior staffers. Claudia Gutjahr-Loeser will manage corporate communications, and Alexander Oehmichen will be general counsel.
Gutjahr-Loeser will be responsible for European corporate communications. She was hired from Cassiopeia, where she was investor relations manager and assistant to the CEO.
Oehmichen joins the company from Abbott GmbH, where he ran the legal department. He also has held positions in business law at Boehringer Mannheim and Knoll.
Structural Bioinformatics said on May 6 that it had brought on Robert Ingersoll as senior director of national sales.
Ingersoll was previously with Johnson and Johnson, and has been a sales executive in various divisions of the company, including Janssen Pharmaceutica and Ortho Pharmaceuticals.
Structural Bioinformatics, which focuses on drug discovery through proteomics, is headquartered in San Diego.
Massachusetts bioinformatics firm AnVil has hired two senior research staff, the company said on May 1.
Kurt Thearling will be director of engineering, and Natasha Markuzon will be an informatics scientist.
Thearling was most recently senior director of development at the Massachusetts software company Wheelhouse.
Markuzon was senior data analyst at Xchange, and is experienced in data mining, predictive modeling, and neural networks.
The CEO and R&D chief of Protein Design Labs resigned last week, the company said on May 1.
PDL co-founder Laurence Jay Korn, 52, resigned as chief executive, but will retain a role with the company as board chair.
Senior Vice President Douglas Ebersole will serve as interim CEO while the board conducts a search for a replacement.
Daniel Levitt, who led PDL's research and development, also resigned. He had been with the company since 1996, when he left his position as chief medical officer and vice president of drug development at Geron.
The company has recently endured several disappointments in drug development, as its psoriasis and non-Hodgkin's lymphoma compounds performed poorly in clinical trials.